Adrenogenital syndrome treatment market seen hitting $20.9 billion by 2033

By AI, Created 9:48 AM UTC, May 20, 2026, /AGP/ – The global adrenogenital syndrome treatment market is projected to rise from $14.3 billion in 2026 to $20.9 billion by 2033 as newborn screening expands and hormone therapy advances. North America leads now, while Asia Pacific is set to grow fastest as more patients are diagnosed and treated earlier.

Why it matters: - Adrenogenital syndrome, often linked to congenital adrenal hyperplasia, needs lifelong endocrine management, which supports steady demand for medicines and monitoring. - Wider newborn screening and earlier diagnosis are improving treatment outcomes and lowering infant mortality tied to adrenal crises. - Broader access to endocrinology care in emerging markets is expected to increase patient identification and therapy use.

What happened: - Persistence Market Research said the global adrenogenital syndrome treatment market is expected to reach US$14.3 billion in 2026 and grow to US$20.9 billion by 2033. - The forecast implies a compound annual growth rate of 5.6% during the period. - The market report was released May 7, 2026, from London. - The report points to rising congenital adrenal hyperplasia diagnoses, stronger newborn screening, and better hormone replacement therapies as the main growth drivers. - A free sample is available here.

The details: - Governments and healthcare agencies are expanding newborn screening programs for endocrine disorders. - Mandatory congenital adrenal hyperplasia screening in several developed countries has improved treatment outcomes and reduced infant mortality linked to adrenal crises. - Increased awareness among healthcare professionals and families is pushing earlier intervention and longer-term disease management. - Improved healthcare infrastructure in emerging economies is widening access to endocrinology services and hormone testing. - Expanding neonatal screening in Asia Pacific and Latin America is expected to raise patient identification rates during the forecast period. - As diagnostic access improves, demand for hormone replacement therapies is expected to rise. - Glucocorticoids are projected to account for nearly 49% of global revenue in 2026. - Hydrocortisone, prednisone and dexamethasone remain widely used to control cortisol deficiency and suppress excess androgen production. - Researchers are developing modified-release formulations designed to better match natural cortisol rhythms and reduce long-term steroid complications. - Steroidogenesis inhibitors are expected to grow the fastest through 2033. - These therapies target enzymes involved in adrenal hormone synthesis and may reduce reliance on high-dose glucocorticoids. - Recent approvals of crinecerfont and pediatric hydrocortisone oral solutions show rising investment in rare endocrine disease treatments. - The report lists glucocorticoids, mineralocorticoids, hormone modulators and steroidogenesis inhibitors by drug class. - It segments disease type into classic CAH salt-wasting, classic CAH simple virilizing and non-classic CAH. - It includes oral, intravenous, intramuscular, subcutaneous and long-acting routes of administration. - It covers North America, Europe, East Asia, South Asia & Oceania, Latin America, and Middle East & Africa. - A custom report request is available here. - The full report is available here.

Between the lines: - The market’s growth is being driven less by a single new drug and more by earlier diagnosis, broader screening, and incremental therapy improvements. - Long-term steroid use still creates clinical tradeoffs, including metabolic complications, hypertension, weight gain and lower bone density. - Adherence remains a challenge, especially for adolescents moving from pediatric to adult endocrine care. - Shortages of trained endocrinologists and limited screening infrastructure continue to slow diagnosis in some developing healthcare systems. - The competitive field remains moderately concentrated, with Novo Nordisk, Neurocrine Biosciences, Crinetics Pharmaceuticals and Spruce Biosciences investing in clinical trials and long-acting or targeted therapies.

What’s next: - North America is expected to keep the largest share in 2026 at nearly 39% of revenue. - The United States remains the main contributor because of clinical research activity and broad access to specialized endocrine care. - Europe is expected to keep growing at a steady pace on the back of universal healthcare systems, orphan disease policies and endocrinology research networks. - Asia Pacific is forecast to grow the fastest through 2033 as healthcare access, awareness and neonatal screening investment rise in China, India, Japan and South Korea. - Future investment in precision medicine, gene therapy research and long-acting hormone delivery systems could reshape congenital adrenal hyperplasia management over the next decade. - More orphan drug approvals and better diagnostic access are likely to open additional commercial opportunities for drugmakers.

The bottom line: - The market’s next leg of growth depends on earlier detection, better long-term endocrine care and new therapies that make lifelong treatment easier to manage.